PRRT2 and leukemia: In contrast, Mitoxantrone, another FDA‐approved drug, inhibits topoisomerase II and PKC at concentrations ranging from nanomolar to low micromolar levels,[26] which are lower than its MCU inhibitory concentration.[7] This difference restricts its clinical application primarily to leukemia treatment, as its MCU inhibitory concentration is not achievable at therapeutic doses without significant toxicity.